Vir Biotechnology (VIR) Share-based Compensation (2018 - 2026)

Vir Biotechnology has disclosed Share-based Compensation across 9 years of filings, most recently posting $12.1 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $12.1 million, down 14.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.1 million (down 31.5% YoY), and the FY2025 annual result was $49.1 million, down 37.45% from the prior year.
• Share-based Compensation came in at $12.1 million for Q1 2026 at Vir Biotechnology, up from $11.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $30.6 million in Q2 2023 to a low of $11.2 million in Q4 2025.
• The 5-year median for Share-based Compensation is $23.8 million (2024), against an average of $20.8 million.
• Across the five-year window, Share-based Compensation jumped 63.56% in 2022 and sank 43.97% in 2024, its largest moves.
• Vir Biotechnology's Share-based Compensation stood at $24.9 million in 2022, then advanced by 13.7% to $28.3 million in 2023, then plunged by 43.97% to $15.8 million in 2024, then fell by 29.26% to $11.2 million in 2025, then grew by 7.86% to $12.1 million in 2026.
• The last three Share-based Compensation figures came in at $12.1 million (Q1 2026), $11.2 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.